Efficacy and safety of etanercept

Etanercept was the first TNF-alpha inhibitor to be approved for first-line treatment of moderate to severe plaque psoriasis and psoriatic arthritis

The authors of this paper have reviewed the available data on its long-term efficacy and safety.

They investigated the results of several clinical trials into patients with psoriasis and psoriatic arthritis who were treated with etanercept. They found etanercept to be effective in the long-term treatment of psoriasis and that it was associated with a significant reduction in the risk of MI. It was also linked with a trend toward a reduction in the prevalence of metabolic syndrome after two years of therapy.

They also found etanercept to be effective in the long-term treatment of psoriatic arthritis, with an associated beneficial effect on the prevention of further radiographic disease progression.

Etanercept was found to be generally well tolerated. Its safety appeared to be similar in patients who tested positive for antibodies to etanercept and in those who tested negative.

The most common reported side-effects were injection site reactions, headache, arthralgia, back pain, URTIs, nasopharyngitis, sinusitis and influenza. Rarer reported severe side-effects included cellulitis, pneumonia, hypoaesthesia, paraesthesia, dyspnoea, viral meningitis, subdural haematoma, MI, nephrolithiasis, depression, basal cell carcinoma and an increased risk of squamous cell carcinoma.

The authors concluded that etanercept has demonstrated long-term efficacy both as monotherapy and in combination with other psoriasis treatments. They also postulated that the risk of severe side-effects is small and the benefit of treating patients with psoriasis with etanercept outweighs the risks.

Kivelevitch D, Mansouri B, Menter A. Biologics 2014; 8: 169-82

Want news like this straight to your inbox?
Sign up for our bulletins

Read these next

Anti-TNF-alpha therapy in plaque psoriasis

Anti-TNF-alpha therapy in plaque psoriasis

Targeting the inflammatory process is known to improve...

Editorial: Update to the NICE guidance on management of psoriasis

Editorial: Update to the NICE guidance on management of psoriasis

The new guidelines update and revise information on...

Psoriasis in children and young adults

Psoriasis in children and young adults

Psoriasis can have a psychological impact, even in...

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases